EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS‐CoV‐2 Infection—Increasing Community Access to Testing Program, United States, January–September 2023

Allison Avrich Ciesla iD, Josephine Mak, Lauren E Roper, Katherine E Fleming-Dutra, Zachary R Smith, Ryan E Wiegand, Amadea Britton, Joseph Miller, Ruth Link-Gelles

Influenza and Other Respiratory Viruses · 2024

DOI: 10.1111/irv.70038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, 2024. Verfasst von Allison Avrich Ciesla und 8 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, SARS-CoV-2, Vaccine Efficacy. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: US Department of Health and Human Services, CDC HHS, Office of the National Coordinator for Health Information Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

On September 2, 2022, bivalent COVID‐19 mRNA vaccines, were recommended to address reduced effectiveness of COVID‐19 monovalent vaccines during SARS‐CoV‐2 Omicron variant predominance.

Methods

Using national pharmacy‐based SARS‐CoV‐2 testing program data from January 15 to September 11, 2023, this test‐negative, case–control design study assessed bivalent COVID‐19 vaccine effectiveness (VE) against symptomatic infection.

Results

VE against symptomatic infection of a bivalent dose between 2 weeks and 1 month after bivalent vaccination ranged from 46% (95% CI: 38%–52%) for those aged ≥ 65 years to 61% (95% CI 41%–75%) for those aged 12–17 years.

Conclusion

Bivalent vaccines protected against symptomatic infection. However, effectiveness waned over time, emphasizing the need to stay up to date with COVID‐19 vaccination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19COVID-19 VaccinesSARS-CoV-2Vaccine EfficacymRNA VaccinesHumansAgedAdolescentMaleFemaleChildUnited StatesCase-Control StudiesMiddle AgedAdultYoung AdultVaccinationVaccines, Synthetic

Stichwörter der Autor:innen

BivalentCOVID‐19SARS‐CoV‐2Symptomatic Infection

Substanzen

COVID-19 VaccinesmRNA VaccinesVaccines, Synthetic

Autor:innen und Institutionen

  • National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Eagle Health Analytics, San Antonio, Texas, USA.
  • Office of Readiness and Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • US Public Health Service Commissioned Corps, Rockville, Maryland, USA.

ORCID-Profile: Allison Avrich Ciesla

Förderung

  • US Department of Health and Human Services
  • CDC HHS
  • Office of the National Coordinator for Health Information Technology
  • Centers for Disease Control and Prevention

Zitieren

APA

Ciesla, A. A., Mak, J., Roper, L. E., Fleming-Dutra, K. E., Smith, Z. R., Wiegand, R. E., Britton, A., Miller, J., & Link-Gelles, R. (2024). Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS‐CoV‐2 Infection—Increasing Community Access to Testing Program, United States, January–September 2023. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.70038

Vancouver

Ciesla AA, Mak J, Roper LE, Fleming-Dutra KE, Smith ZR, Wiegand RE, et al. Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS‐CoV‐2 Infection—Increasing Community Access to Testing Program, United States, January–September 2023. Influenza and Other Respiratory Viruses. 2024. doi:10.1111/irv.70038

BibTeX
@article{Ciesla2024,
  author = {Ciesla, Allison Avrich and Mak, Josephine and Roper, Lauren E and Fleming-Dutra, Katherine E and Smith, Zachary R and Wiegand, Ryan E and Britton, Amadea and Miller, Joseph and Link-Gelles, Ruth},
  title = {Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS‐CoV‐2 Infection—Increasing Community Access to Testing Program, United States, January–September 2023},
  journal = {Influenza and Other Respiratory Viruses},
  year = {2024},
  doi = {10.1111/irv.70038}
}
Kostenlos starten →